NO326155B1 - 2H-pyridazin-3-onderivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen, anvendelse som medikamenter og farmasoytiske preparater - Google Patents

2H-pyridazin-3-onderivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen, anvendelse som medikamenter og farmasoytiske preparater Download PDF

Info

Publication number: NO326155B1
Authority: NO; Norway
Prior art keywords: formula; pyridazin; derivative; acid addition; group
Prior art date: 2001-07-26

Application number

NO20040268A

Other languages

English (en)

Norwegian (no)

Other versions

NO20040268L (no

Inventor

Aniko Miklosne Kovacs

Istvan Gacsalyi

Jozsef Barkoczy

Janos Wellmann

Katalin Pallagi

Peter Kotay Nagy

Gyorgy Levay

Andras Egyed

Gyula Simig

Judit Raczne Bajnogel

Eva Schmidt

Gabor Szenasi

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-26

Filing date

2004-01-20

Publication date

2008-10-13

2004-01-20 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

2004-03-23 Publication of NO20040268L publication Critical patent/NO20040268L/no

2008-10-13 Publication of NO326155B1 publication Critical patent/NO326155B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 21
239000004480 active ingredient Substances 0.000 title claims description 15
238000000034 method Methods 0.000 title claims description 14
239000003814 drug Substances 0.000 title claims description 9
239000008194 pharmaceutical composition Substances 0.000 title 2
150000001875 compounds Chemical class 0.000 claims description 54
239000002253 acid Substances 0.000 claims description 46
150000003839 salts Chemical class 0.000 claims description 46
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims description 37
239000000825 pharmaceutical preparation Substances 0.000 claims description 24
229910052739 hydrogen Inorganic materials 0.000 claims description 22
229910052801 chlorine Inorganic materials 0.000 claims description 21
125000005843 halogen group Chemical group 0.000 claims description 17
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
239000000460 chlorine Substances 0.000 claims description 16
229910052740 iodine Inorganic materials 0.000 claims description 14
MRMGJMGHPJZSAE-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 MRMGJMGHPJZSAE-UHFFFAOYSA-N 0.000 claims description 11
230000000701 neuroleptic effect Effects 0.000 claims description 10
-1 alkylamine pyridazin-3-one derivative Chemical class 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
230000002996 emotional effect Effects 0.000 claims description 7
230000003340 mental effect Effects 0.000 claims description 6
231100000252 nontoxic Toxicity 0.000 claims description 4
230000003000 nontoxic effect Effects 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
150000008316 benzisoxazoles Chemical class 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
MWBRMKAAQVRANL-UHFFFAOYSA-N 6-chloro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(Cl)=CC=C2C=1C1CCNCC1 MWBRMKAAQVRANL-UHFFFAOYSA-N 0.000 claims 1
239000012050 conventional carrier Substances 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
230000000694 effects Effects 0.000 description 22
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 21
239000000203 mixture Substances 0.000 description 17
241001465754 Metazoa Species 0.000 description 16
208000024891 symptom Diseases 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
238000012360 testing method Methods 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 12
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
201000000980 schizophrenia Diseases 0.000 description 12
239000012043 crude product Substances 0.000 description 11
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 11
230000004044 response Effects 0.000 description 11
230000001143 conditioned effect Effects 0.000 description 10
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
229960004170 clozapine Drugs 0.000 description 9
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
238000002844 melting Methods 0.000 description 9
230000008018 melting Effects 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
238000003756 stirring Methods 0.000 description 8
238000005160 1H NMR spectroscopy Methods 0.000 description 7
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
230000009194 climbing Effects 0.000 description 6
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
229910000027 potassium carbonate Inorganic materials 0.000 description 6
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 6
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 5
229960004046 apomorphine Drugs 0.000 description 5
230000037396 body weight Effects 0.000 description 5
125000001309 chloro group Chemical group Cl* 0.000 description 5
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000005259 measurement Methods 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
229950010883 phencyclidine Drugs 0.000 description 5
208000009132 Catalepsy Diseases 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
206010047853 Waxy flexibility Diseases 0.000 description 4
230000001451 cardiotoxic effect Effects 0.000 description 4
229960001076 chlorpromazine Drugs 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000006399 behavior Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000037024 effective refractory period Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
229960003878 haloperidol Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000013016 learning Effects 0.000 description 3
239000012452 mother liquor Substances 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
210000003540 papillary muscle Anatomy 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 2
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 2
206010012239 Delusion Diseases 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
101150104779 HTR2A gene Proteins 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
231100000457 cardiotoxic Toxicity 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000001484 cataleptigenic effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000008602 contraction Effects 0.000 description 2
239000007799 cork Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000006735 deficit Effects 0.000 description 2
231100000868 delusion Toxicity 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000035929 gnawing Effects 0.000 description 2
230000004886 head movement Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
231100000500 noncardiotoxic Toxicity 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
125000006308 propyl amino group Chemical group 0.000 description 2
230000011514 reflex Effects 0.000 description 2
229960001534 risperidone Drugs 0.000 description 2
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000004006 stereotypic behavior Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
FYWJPPNFCQDMDJ-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1C1=NOC2=CC(F)=CC=C12 FYWJPPNFCQDMDJ-UHFFFAOYSA-N 0.000 description 1
LAQJGAKLLZAETL-UHFFFAOYSA-N 2h-pyrazin-3-one Chemical class O=C1CN=CC=N1 LAQJGAKLLZAETL-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ACKBTCUMGAHRIE-UHFFFAOYSA-N 4,5-dichloro-2-methylpyridazin-3-one Chemical compound CN1N=CC(Cl)=C(Cl)C1=O ACKBTCUMGAHRIE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
BQNLTXZVZWVEDX-UHFFFAOYSA-N 4-chloro-5-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethylamino]-2-methylpyridazin-3-one Chemical compound O=C1N(C)N=CC(NCCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)=C1Cl BQNLTXZVZWVEDX-UHFFFAOYSA-N 0.000 description 1
TUTAQRPLNNBCAU-UHFFFAOYSA-N 5-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propylamino]-2-methylpyridazin-3-one Chemical compound O=C1N(C)N=CC(NCCCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)=C1 TUTAQRPLNNBCAU-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010061533 Myotonia Diseases 0.000 description 1
238000011785 NMRI mouse Methods 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010042008 Stereotypy Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
229960003990 apomorphine hydrochloride Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003693 atypical antipsychotic agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
244000309464 bull Species 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000002903 catalepsic effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000004970 emotional disturbance Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000026781 habituation Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000035873 hypermotility Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
229960003162 iloperidone Drugs 0.000 description 1
XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
210000001009 nucleus accumben Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940035004 seroquel Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20040268A 2001-07-26 2004-01-20 2H-pyridazin-3-onderivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen, anvendelse som medikamenter og farmasoytiske preparater NO326155B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0103063A HU225955B1 (en)	2001-07-26	2001-07-26	Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
PCT/HU2002/000072 WO2003010166A1 (fr)	2001-07-26	2002-07-24	Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif

Publications (2)

Publication Number	Publication Date
NO20040268L NO20040268L (no)	2004-03-23
NO326155B1 true NO326155B1 (no)	2008-10-13

Family

ID=89979562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040268A NO326155B1 (no)	2001-07-26	2004-01-20	2H-pyridazin-3-onderivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen, anvendelse som medikamenter og farmasoytiske preparater

Country Status (27)

Country	Link
US (1)	US7098210B2 (fr)
EP (1)	EP1417206B1 (fr)
JP (1)	JP4249012B2 (fr)
KR (1)	KR100909514B1 (fr)
CN (1)	CN1247571C (fr)
AR (2)	AR036248A1 (fr)
AT (1)	ATE466859T1 (fr)
AU (1)	AU2002321669B8 (fr)
BR (1)	BR0211440A (fr)
CA (1)	CA2453917C (fr)
CY (1)	CY1110240T1 (fr)
CZ (1)	CZ2004123A3 (fr)
DE (1)	DE60236294D1 (fr)
DK (1)	DK1417206T3 (fr)
EA (1)	EA006246B1 (fr)
ES (1)	ES2345541T3 (fr)
HU (1)	HU225955B1 (fr)
MA (1)	MA27867A1 (fr)
MX (1)	MXPA04000814A (fr)
NO (1)	NO326155B1 (fr)
NZ (1)	NZ531154A (fr)
PL (1)	PL206824B1 (fr)
PT (1)	PT1417206E (fr)
SI (1)	SI1417206T1 (fr)
SK (1)	SK552004A3 (fr)
WO (1)	WO2003010166A1 (fr)
ZA (1)	ZA200400482B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU227255B1 (en) *	2002-04-26	2010-12-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient
EP1904995A4 (fr)	2005-06-08	2011-01-05	Ignis Innovation Inc	Procede et systeme permettant de commander un affichage a dispositif electroluminescent
WO2007079572A1 (fr)	2006-01-09	2007-07-19	Ignis Innovation Inc.	Procédé et système pour entraîner un circuit d’affichage de matrice active
US9489891B2 (en)	2006-01-09	2016-11-08	Ignis Innovation Inc.	Method and system for driving an active matrix display circuit
US9269322B2 (en)	2006-01-09	2016-02-23	Ignis Innovation Inc.	Method and system for driving an active matrix display circuit
HUP0600555A3 (en) *	2006-07-03	2008-10-28	Egis Gyogyszergyar Nyrt	Use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]izoxazol-3-yl)piperidin-1-yl]ethylamino}2-methyl-3(2h)-piridazinon for the production of pharmaceutical compositions for influencing cognitive functions and causing neuroprotective effect
TW200949807A (en)	2008-04-18	2009-12-01	Ignis Innovation Inc	System and driving method for light emitting device display
CA2637343A1 (fr)	2008-07-29	2010-01-29	Ignis Innovation Inc.	Amelioration de pilote de source d'affichage
US9370075B2 (en)	2008-12-09	2016-06-14	Ignis Innovation Inc.	System and method for fast compensation programming of pixels in a display
US8283967B2 (en)	2009-11-12	2012-10-09	Ignis Innovation Inc.	Stable current source for system integration to display substrate
CA2687631A1 (fr)	2009-12-06	2011-06-06	Ignis Innovation Inc	Mecanisme de commande a faible puissance pour applications d'affichage
CA2696778A1 (fr)	2010-03-17	2011-09-17	Ignis Innovation Inc.	Procedes d'extraction des parametres d'uniformite de duree de vie
US9886899B2 (en)	2011-05-17	2018-02-06	Ignis Innovation Inc.	Pixel Circuits for AMOLED displays
US9351368B2 (en)	2013-03-08	2016-05-24	Ignis Innovation Inc.	Pixel circuits for AMOLED displays
US20140368491A1 (en)	2013-03-08	2014-12-18	Ignis Innovation Inc.	Pixel circuits for amoled displays
CN103597534B (zh)	2011-05-28	2017-02-15	伊格尼斯创新公司	用于快速补偿显示器中的像素的编程的系统和方法
US9747834B2 (en)	2012-05-11	2017-08-29	Ignis Innovation Inc.	Pixel circuits including feedback capacitors and reset capacitors, and display systems therefore
US9336717B2 (en)	2012-12-11	2016-05-10	Ignis Innovation Inc.	Pixel circuits for AMOLED displays
US9786223B2 (en)	2012-12-11	2017-10-10	Ignis Innovation Inc.	Pixel circuits for AMOLED displays
WO2014124755A1 (fr)	2013-02-18	2014-08-21	Jürgen Von Der Ohe	Procédé et dispositif de nettoyage au jet froid
CA2894717A1 (fr)	2015-06-19	2016-12-19	Ignis Innovation Inc.	Caracterisation d'un dispositif optoelectronique au moyen d'une ligne de sens partage
US9721505B2 (en)	2013-03-08	2017-08-01	Ignis Innovation Inc.	Pixel circuits for AMOLED displays
CA2873476A1 (fr)	2014-12-08	2016-06-08	Ignis Innovation Inc.	Architecture d'affichage de pixels intelligents
CA2886862A1 (fr)	2015-04-01	2016-10-01	Ignis Innovation Inc.	Ajustement de la luminosite d'affichage en vue d'eviter la surchauffe ou le vieillissement accelere
US10373554B2 (en)	2015-07-24	2019-08-06	Ignis Innovation Inc.	Pixels and reference circuits and timing techniques
CA2898282A1 (fr)	2015-07-24	2017-01-24	Ignis Innovation Inc.	Etalonnage hybride de sources de courant destine a des afficheurs a tension polarisee par courant programmes
US10657895B2 (en)	2015-07-24	2020-05-19	Ignis Innovation Inc.	Pixels and reference circuits and timing techniques
CA2908285A1 (fr)	2015-10-14	2017-04-14	Ignis Innovation Inc.	Pilote comportant une structure de pixel a plusieurs couleurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE62890B1 (en)	1988-12-06	1995-03-08	Hafslund Nycomed Pharma	New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
IL117646A (en) *	1995-04-12	2000-06-01	Ferrer Int	7-¬3-¬4-(6-fluoro-1,2-benzisoxazole-3-YL)piperidin-1-YL¾propoxy¾3-alkyl-chromen-4-ones their preparation their uses and pharmaceutical compositions comprising them

2001
- 2001-07-26 HU HU0103063A patent/HU225955B1/hu not_active IP Right Cessation
2002
- 2002-07-24 AT AT02755381T patent/ATE466859T1/de active
- 2002-07-24 WO PCT/HU2002/000072 patent/WO2003010166A1/fr not_active Ceased
- 2002-07-24 JP JP2003515525A patent/JP4249012B2/ja not_active Expired - Fee Related
- 2002-07-24 DK DK02755381.7T patent/DK1417206T3/da active
- 2002-07-24 PT PT02755381T patent/PT1417206E/pt unknown
- 2002-07-24 DE DE60236294T patent/DE60236294D1/de not_active Expired - Lifetime
- 2002-07-24 PL PL367447A patent/PL206824B1/pl unknown
- 2002-07-24 SK SK55-2004A patent/SK552004A3/sk unknown
- 2002-07-24 AU AU2002321669A patent/AU2002321669B8/en not_active Ceased
- 2002-07-24 EA EA200400223A patent/EA006246B1/ru not_active IP Right Cessation
- 2002-07-24 US US10/484,619 patent/US7098210B2/en not_active Expired - Fee Related
- 2002-07-24 CZ CZ2004123A patent/CZ2004123A3/cs unknown
- 2002-07-24 CA CA002453917A patent/CA2453917C/fr not_active Expired - Fee Related
- 2002-07-24 ES ES02755381T patent/ES2345541T3/es not_active Expired - Lifetime
- 2002-07-24 CN CNB028163737A patent/CN1247571C/zh not_active Expired - Fee Related
- 2002-07-24 NZ NZ531154A patent/NZ531154A/en not_active IP Right Cessation
- 2002-07-24 EP EP02755381A patent/EP1417206B1/fr not_active Expired - Lifetime
- 2002-07-24 BR BR0211440-2A patent/BR0211440A/pt active Search and Examination
- 2002-07-24 MX MXPA04000814A patent/MXPA04000814A/es active IP Right Grant
- 2002-07-24 KR KR1020047001151A patent/KR100909514B1/ko not_active Expired - Fee Related
- 2002-07-24 SI SI200230914T patent/SI1417206T1/sl unknown
- 2002-07-26 AR ARP020102834A patent/AR036248A1/es not_active Application Discontinuation
2004
- 2004-01-19 MA MA27487A patent/MA27867A1/fr unknown
- 2004-01-20 NO NO20040268A patent/NO326155B1/no not_active IP Right Cessation
- 2004-01-22 ZA ZA2004/00482A patent/ZA200400482B/en unknown
2010
- 2010-07-22 CY CY20101100690T patent/CY1110240T1/el unknown
2012
- 2012-11-08 AR ARP120104216A patent/AR088808A2/es unknown

Also Published As

Publication number	Publication date
DE60236294D1 (de)	2010-06-17
EA006246B1 (ru)	2005-10-27
MXPA04000814A (es)	2004-05-21
KR100909514B1 (ko)	2009-07-27
BR0211440A (pt)	2004-07-20
HK1067626A1 (en)	2005-04-15
PL206824B1 (pl)	2010-09-30
AU2002321669B8 (en)	2008-06-05
HUP0103063A2 (hu)	2003-02-28
HUP0103063A3 (en)	2005-06-28
WO2003010166A1 (fr)	2003-02-06
CN1545513A (zh)	2004-11-10
US20040171619A1 (en)	2004-09-02
JP2004538293A (ja)	2004-12-24
ZA200400482B (en)	2005-05-25
AR036248A1 (es)	2004-08-25
PT1417206E (pt)	2010-07-29
PL367447A1 (en)	2005-02-21
CA2453917C (fr)	2009-06-23
AU2002321669B2 (en)	2008-05-15
NO20040268L (no)	2004-03-23
EA200400223A1 (ru)	2004-12-30
AU2002321669A2 (en)	2003-02-17
SK552004A3 (en)	2004-08-03
KR20040030862A (ko)	2004-04-09
SI1417206T1 (sl)	2010-09-30
CA2453917A1 (fr)	2003-02-06
CZ2004123A3 (cs)	2004-05-12
HU225955B1 (en)	2008-01-28
CN1247571C (zh)	2006-03-29
AR088808A2 (es)	2014-07-10
ES2345541T3 (es)	2010-09-27
EP1417206B1 (fr)	2010-05-05
EP1417206A1 (fr)	2004-05-12
US7098210B2 (en)	2006-08-29
JP4249012B2 (ja)	2009-04-02
NZ531154A (en)	2005-09-30
ATE466859T1 (de)	2010-05-15
DK1417206T3 (da)	2010-08-16
MA27867A1 (fr)	2006-05-02
CY1110240T1 (el)	2015-01-14
HU0103063D0 (en)	2001-10-28

Legal Events

Date	Code	Title	Description
2018-02-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO326155B1 (no)	2008-10-13	2H-pyridazin-3-onderivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen, anvendelse som medikamenter og farmasoytiske preparater
AU2002321669A1 (en)	2003-05-29	Novel 2H-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
JP4485353B2 (ja)	2010-06-23	有効な抗ヒスタミン剤および抗アレルギー剤としての新規インドリルピペリジン誘導体
JPH05279357A (ja)	1993-10-26	アザヘテロサイクリルメチル−クロマン類
US5670522A (en)	1997-09-23	Dopamine receptor subtype ligands
JP2003501424A (ja)	2003-01-14	抗ヒスタミンおよび抗アレルギー剤としてのインドリルピペリジン誘導体
WO1994024105A1 (fr)	1994-10-27	Derives d'indole utiles comme antagonistes de la dopamine d4
JP6585718B2 (ja)	2019-10-02	抗ヒスタミン剤としての新規ベンゾイミダゾール誘導体
TW201124391A (en)	2011-07-16	2-substituted-ethynylthiazole derivatives and uses of same
JP2660430B2 (ja)	1997-10-08	新規の１，２，５，６−テトラヒドロピリジン−３−カルボキサアルデヒドのオキシム誘導体、それらの製造方法、それらの薬剤としての使用及びそれらを含有する組成物
US4243666A (en)	1981-01-06	4-Amino-2-piperidino-quinazolines
DE60118434T2 (de)	2006-12-14	Indolylpiperidinderivate als antihistaminische und antiallergische mittel
EP0765323B1 (fr)	2001-07-11	Derives de 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one, leur preparation et leur utilisation dans le traitement des psychoses, de la schizophrenie et de l'anxiete
HK1067626B (en)	2010-10-15	Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
EP0794185A1 (fr)	1997-09-10	Compose thiazole bicyclique
JPWO1996016968A1 (ja)	1997-12-22	二環性チアゾール化合物
JPH09291090A (ja)	1997-11-11	ピペリジノンおよびホモピペリジノン誘導体
HUP9903042A2 (hu)	2002-01-28	Alkil-piperidinil-benzo[d]izoxazol-származékok, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására